The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
September 19th 2024
EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.
September 12th 2024
September 10th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Mavacamten Can Reduce Need for Surgery in Hypertrophic Cardiomyopathy
April 2nd 2022Results of the VALOR-HCM trial indicate patients with hypertrophic cardiomyopathy could reduce their need for septal reduction therapy and improve quality of life with use of mavacamten, a selective cardiac myosin inhibitor from Bristol Myers Squibb.
Wearable Tech for Cardiac Monitoring May Give Spotty, Inaccurate Data Depending on Skin Tones
March 29th 2022A systematic review from ACC.22 suggests wearable technology, specifically those for assessing heart rate and arrhythmias, may be less accurate when used by individuals with darker skin tones.
Q&A: Long-Term Cardiovascular Risk of COVID-19, with Ziyad Al-Aly, MD
March 25th 2022Lead investigator of a recent study assessing risk of long-term COVID-19 risk using data from more than 11 million patients, Ziyad Al-Aly, MD, sits down with Practical Cardiology for a Q&A on the findings from his research.
Early Aspirin Use Could Lower Mortality, Odds of Stroke in COVID-19
March 24th 2022An analysis of data from more than 110k hospitalized patients with COVID-19 suggests aspirin use on the first day of hospitalization was linked to lower odds for both in-hospital mortality and pulmonary embolism in weighted analyses.
Antiplatelet Therapy Unlikely to Improve Organ Support-Free Days in COVID-19
March 23rd 2022Data from the REMAP-CAP trial suggests use of aspirin or P2Y12 inhibitors had a low likelihood of improving organ support-free days in critically ill patients with COVID-19 within 21 days compared to no antiplatelet therapy.
Cost-Effectiveness Data Supports Use of Salt Substitute Based on SSaSS Findings
March 21st 2022Data from a within-trial cost-effectiveness evaluation of data from the Salt Substitute and Stroke Study suggest use of the 75% sodium chloride 25% potassium chloride salt substitute had a 95% probability of being cost-saving and a greater than 99.9% probability of being cost-effective.